RGCC Group was established in 2004 and is one of the most pioneering
companies of the life science industry world-wide.

The company specializes in the fields of medical genetics and, in particular, cancer genetics, chemo-sensitivity and chemo-resistance testing and in research and development within the pharmaceutical industry. The company headquarters are locaded in Switzerland, and our brand new, state-of-the art facilities in northern Greece are equipped with the most up-to-date technologically advanced equipment and specialized software for data analysis.

RGCC is a global organization working in collaboration with branch offices and distributors to provide a world-wide service.

The activities of R.G.C.C. can be divided into two main sectors. The clinical services include detection, immunophenotyping and isolation of circulating tumor cells using state of the art flow cytometers and sensitivity/chemoresistance testing using micro-array technology. High throughput screening is used to provide an automated and fast method for sample processing as well as screening different types of libraries, including combinatorial chemistry, genomics, protein and peptide libraries.

R.G.C.C. S.A., the laboratories of R.G.C.C. Group, meets international standards, certified by ISO Accreditation certification No.860-02